摘要
目的:探讨前列地尔对慢性心力衰竭患者血管性假血友病因子(von Willebrand factor,vWF)和纤溶酶原激活物抑制物-1(plasminogen activator inhibitor-1,PAI-1)的影响。方法:102例慢性心力衰竭患者,随机分为前列地尔组和对照组各51例,两组患者均给予标准强心、利尿和扩血管等药物治疗。前列地尔组在标准治疗的基础上加用前列地尔。结果:前列地尔组和对照组vWF均明显下降,前列地尔组更为明显。前列地尔组和对照组PAI-1均明显下降,前列地尔组更为明显。结论:前列地尔能明显降低慢性心力衰竭患者vWF和PAI-1的水平,较常规治疗进一步减少vWF和PAI-1,改善心功能,减少心血管事件。
Objective： To investigate the effects of Alprostadil on von Willebrand factor（vWF）and plasminogen activator inhibitor-1（PAI-1） in patients with chronic heart failure.Methods：102 cases of chronic heart failure were randomly assigned to alprostadil group and control group 51 cases.All patients were given a standard cardiac,diuretic and vasodilator drug therapy.Alprostadil group was plused alprostadil.on the basis of the standard treatment.Results：The plasma vWF decreased significantly in the alprostadil therapy group and the control group.Alprostadil group is more obvious.The plasma PAI-1 decreased significantly in the alprostadil therapy group and the control group.Alprostadil group is more obvious.Conclusion：Alprostadil can significantly reduce vWF and PAI-1 levels than conventional treatment in patients with chronic heart failure,improve heart function and reduce cardiovascular events.
出处
《河南医学研究》
CAS
2012年第2期194-196,共3页
Henan Medical Research
